RecruitingPhase 1NCT06977724

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AbbVie
Principal Investigator: ABBVIE INC.
AbbVie
Intervention: ABBV-319(drug)
Enrollment: 36 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2025 – 2029

Study locations (6)

Life Clinical Trials /ID# 276050, Margate, Florida, United States
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836, Tampa, Florida, United States
Private Practice - Dr. Ramesh C. Gupta I /ID# 275826, Memphis, Tennessee, United States
Integrative Rheumatology of South Texas - Harlingen /ID# 276458, Harlingen, Texas, United States
Amsterdam UMC, locatie AMC /ID# 274286, Amsterdam, North Holland, Netherlands
Universitair Medisch Centrum Utrecht /ID# 273398, Utrecht, Netherlands

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06977724 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials